The Clorox Company (CLX)

FairStock Score: 65/100 — STEADY

Key Financials

Strengths

• Dominant brand portfolio in essential consumer categories with demonstrated pricing power
• Strong free cash flow generation ($1.0B) providing flexibility for dividends and debt reduction
• Low beta of 0.57 provides portfolio stability during market volatility
• Four diversified business segments (Health & Wellness, Household, Lifestyle, International) reducing concentration risk
• Recession-resistant products with consistent demand regardless of economic cycles

Concerns

• Extremely high debt-to-equity ratio of 91.91% creates financial inflexibility and refinancing risk
• EV/EBITDA of 57.55 represents extreme valuation premium—paying $57 for every dollar of operating earnings
• Weak Altman Z-Score of 1.86 indicates financial distress territory despite apparent profitability
• Minimal FCF yield of 1.9% provides inadequate return on capital deployment

AI Analysis

Clorox presents the classic characteristics of a mature, defensive business with a genuine economic moat—yet I find the current valuation problematic. The company commands strong brand equity across essential household products with pricing power demonstrated through inflationary periods. Their free cash flow of $1.0B against a $14B market cap yields only 1.9%, which concerns me deeply. At a P/E of 17.37 and EV/EBITDA of 57.55, we're paying a premium price for a slow-growth defensive business. The latest quarter showed net margins of 9.38% on $1.7B revenue—respectable but uninspiring. What troubles me most is the capital structure: a debt-to-equity ratio of 91.91% combined with an Altman Z-Score of 1.86 suggests financial stress. The Piotroski F-Score of 7/9 indicates moderately healthy operations, yet the ROE of 987.18% is an accounting artifact reflecting negative book value, masking true returns on equity. The low beta of 0.57 confirms this is defensive terrain, but defensive doesn't mean cheap. I'm seeing a cash cow trading at growth stock multiples—a dangerous proposition. Unless we see significant deleveraging or dramatic operational improvements, this fails my margin of safety test.

Bull Case

Clorox's essential product portfolio ensures resilient cash flows regardless of economic conditions, supporting its ability to service debt and return capital to shareholders. Strategic margin improvements and successful deleveraging could dramatically enhance shareholder returns, while the brand fortress allows for pricing increases that offset inflationary pressures.

Bear Case

The excessive leverage combined with premium valuation creates a dangerous combination—any economic downturn threatening revenue could quickly trigger covenant violations and forced asset sales. The modest growth trajectory paired with high borrowing costs means returns for equity investors may remain depressed for years despite underlying business quality.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer